EORTC Gynecological Cancer Group (GCG) Meeting VENUE : HOTEL SANTA CATALINA. LEÓN Y CASTILLO, 227. 35005 LAS PALMAS DE GRAN CANARIA RECOMMENDED HOTEL: SANTA CATALINA (HTTP ://WWW.HOTELSANTACATALINA.COM). (ALTERNATIVE HOTEL : EXE CANTERAS, PORTUGAL, 68) LAS PALMAS DE GRAN CANARIA (CANARY ISLANDS, SPAIN) DATES : FRIDAY 17TH AND SATURDAY 18TH OCTOBER 2014 Friday 17 th October 2014 Time slot Topic / Title of presentation Name of speakers/room 08.30-10.00 Young investigator meeting (Part I) Open meeting 10.00-10.15 Coffee break 10.15-12.15 Special session. EORTC GCG Immunotherapy platform. Introduction. Dr. Emad Shash. Specta as a model (15 ) Cellular based immunotherapy for ovarian cancer. Center of Experimental Therapeutics (Lausanne). Prof. Lana Kandalaft. (35 ) Therapeutic vaccines on gynecological cancer. Dr. Suzy Scholl (20 ) Vaccines and immunotherapy research at Nijmegen.Dr. Nelleke Ottevanger (15 ) Overview on HPV trials and an update on recent advances on HPV research. Prof. Gemma Kenter: (20 ) 12.15-13.00 Launch TBA 13.00-13.05 EORTC GCG General Assembly and Business meeting Welcome and information on the meeting A. Casado, Mario Federico, Pedro Lara
13.05-14.10 Ovarian Tumor Site Committee. P. Ottevanger (Chair), I. Vergote, A. Casado, D. Katsaros, I. Boere, L. Vidal, A. Wolfer Reserve: A. Westermann. Report on accepted EORTC HQ and GCG trials (30-35 ) EORTC 55092 (part II): randomized phase II trial of pazopanib and weekly paclitaxel / carboplatin in recurrent platin resistant and refractory ovarian carcinoma (EORTC PI: I. Vergote). Dr. N. Ottevanger, Prof. I. Vergote, Dr. Anneke Westermann, Dr. Anita Wolfer, Dr. A. Casado DGCG/NCRI (GCIG/ENGOT proposal). EORTC 1212. Vargatef (Nintedanib, BIBF1120) in recurrent clear cell ovarian and endometrial cancer (EORTC GCG PI: A. Westermann). Endorsed by the EORTC Ex Co on 14th June 2012. New proposals under discussion (35-40 ) New proposals (immunotherapy) from Lausanne. Dr. A. Wolfer (15-20 ). New proposals (N. Ottevanger) (15 ) 14.10-15.10 Endometrial Tumor Site Committee. A. Casado or N. Ottevanger on behalf of F. Amant (Chair), R. Verheijen, A. Nordin, J van der Velden, M. Romeo, F. Herrera, F. Mota (tbc) Report on accepted EORTC HQ and GCG trials Dr. Antonio Casado, Dr. Nelleke Ottevanger, Dr. Nick Reed, Prof. Ignace Vergote, Dr. Emad Shash, Dr. R. Verheijen/E. Van Dorst GOG-UC1009/EORTC 55116-62114: A phase III randomized trial of gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited high grade uterine leiomyosarcoma (GOG PI: Martee Hensley, EORTC GCG PI: N. Ottevanger). Endorsed by PRC on 3 rd January 2012 (15 ). P. Ottevanger, E. Shash. EORTC 62113-55115. EORTC/CRUK/NCI. A randomized phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUS) after stabilization or response to chemotherapy following surgery or in metastatic first line treatment. (EORTC PI: I. Ray Coquard. EORTC GCG PI: N. Reed). Endorsed by PRC on 14 th March 2012 and last amendment s approval on 31 st January 2013 (12 ). N. Reed, E. Shash. EORTC 55112-62111. Efficacy of aromatase inhibitors in primary advanced or recurrent endometrial stromal sarcoma: a phase II trial (EORTC GCG PI: F. Amant). Endorsed by PRC on 27 th July 2012 (15 ). Amendments to protocol approved in the IRCI meeting in June 2013, but re-discussions took place at the last IRCI meeting (June 2014). New proposals (A. Casado, All) 15.10-15.30 Coffee break
15.30-16.45 Cervix Tumor Site Committee. G. Kenter (Chair), A. Sadozye, L. van Doorn, Elzbieta van der Steen, A. Ferrero, M. Huizing, M. Snidiaki (tbc) REPORT from the new ROG-EORTC GCG GYNECOLOGIC WORKING PARTY (Dr. Fernanda Herrera, Dr. Laura Vidal) (10-15 ). Dr. Gemma Kenter, Dr. Suzy Scholl, Dr. Fernanda Herrera, Dr. E. Shash, Ellen Peeters, Prof. Roman Rouzier, Dr. A. Ferrero New proposals New proposals on immunotherapy approaches. A Phase II/III Clinical Trial of Chemo-radiotherapy in combination with VGX-3100 and INO-9012 in Patients with Locally Advanced Cervical Cancer. EORTC 1411. Dr. Fernanda Herrera (CHUV) (15 ). Endorsed by the PRC on 16 th May 2014 New proposals from Curie: A randomized phase II study of HPV therapeutic vaccine Transgene TG4001 combined with anti-pd-1 antibody for patients with cervical cancer (S. Scholl, Curie) (15-20 ) New proposals and Potential collaboration with the ROG Vulvar cancer proposal/s. Prof. Roman Rouzier. Dr. Manuel Rodrigues and Dr. Johanna Wassermann (Curie) (20) (TBC) The "elderly and cervix project" (Dr. Johanna Wassermann) (TBC). Auditorium 16.45-17.30 Reports on ongoing/recently closed trials EORTC 55994 neoadjuvant cervix trial: Update on the status of the status of EORTC 55994. G. Kenter (15 ) Update on TR combined proposal (TRAC review) and paraffin blocks collections (G. Kenter, N. Ottevanger, E. Shash and E. Peeters) EORTC 55092: Phase Ib of pazopanib and weekly paclitaxel / carboplatin in recurrent platin resistant and refractory ovarian carcinoma (EORTC PI: I. Vergote) (15 ) ENGOT-EN2-DGCG / EORTC 55102 study. A phase III trial of postoperative chemotherapy or no further treatment for patients with stage I-II medium or high risk endometrial cancer. (DGCG PI: M. Raza Mirza. EORTC PI: F. Amant). Endorsed by PRC on 5 th March 2012. Amendment 4 endorsed by PRC in February 2014 (15 ). A. Casado/E. Shash on behalf of F. Amant Auditorium 17.30-18.45 General Assembly and Business meeting (A. Casado) EORTC HQ report (June 2014) (A. Casado, E. Shash) (10 ) SAC review 2013 and EORTC GCG scientific strategy (A. Casado, P. Ottevanger ) (15 ) EORTC GCG future meetings (A. Casado) (5 )
New applications and reapplications/changes in personnel (P. Ottevanger) (10 ) Financial report (I. Vergote) (15 ) Elections of new EORTC GCG officers for 2015-2018: Chair, Secretary and Treasurer (35-40 ). 20.00 Dinner Hotel Santa Catalina TBA 8.30-13.00 Saturday 18 th October 2014 8.30-9.10 Young investigator meeting. Part II. Voting and selection of new proposals 9.10-10.00 Report on survivorships issues -An update on the overview of this program. EORTC HQ personnel (E. Shash, C. Coens) - Psychological distress related to the FU visits - patients preferences re time schedule and examinations - patients concerns - sexual health issues Dr. Eleonora van Dorst, E. Shash, C. Coens, A. Casado, N. Ottevanger -Fertility issues, sexuality and early menopause. -Lymphedema New proposals (E. van Dorst) 10.00-10.15 Coffee break 10.15-11.10 Translational Research Subcommittee (Suzy Scholl, P. Berns) ESGO/ENGOT INTEGRATE initiative (A. Casado) (5 ) OMICs PH5 (Suzy Scholl) Discussions on BioRaids participation (Dr. Suzy Scholl) Targeted therapies in cervical cancer. Dr. Manuel Rodrigues proposal (Curie) (15 ) (TBC) 11.10-11.30 Surgical Subcommittee (E. Van Dorst) -A proposal for endometrial cancer 11.30-12.15 PROTOCOL COMMITTEE (A. Casado /I. Vergote) Summary of discussions Presentations to re-discuss or clarify specific points if needed Voting for new proposals (TBC) 12.15-12.50 Report on GCIG and ENGOT -GCIG activities and future meetings GCIG brainstorming meeting on cervix cancer on 6 th Nov in Melbourne) 5 th OCCC (Tokyo, 2015) E. van Dorst, P. Coronado, I. Zapardiel, R. Rouzier PC members * A. Casado, N. Ottevanger, I. Vergote, E. Shash
GCIG report (A. Casado, N. Ottevanger) -ENGOT phase I/II and TR platforms (I. Vergote, A. Casado) -ENGOT GCA activities (A. Casado, I. Boere) -ENGOT report (A. Casado, N. Ottevanger, E. Sash) 13.00 Official scientific meeting closes Next EORTC GCG meeting: EGAM 12th 13th March, 2015, Brussels (Crowne Plaza Hotel) * PC members: I. Vergote (Leuven, Chair PC and Treasurer), A. Casado (Madrid, Chair EORTC GCG), F. Amant (Leuven, Chair Corpus TSC), G. Kenter (Amsterdam, Chair Cervix TSC), F. Herrera (Chair Radiotherapy subcommittee), E. van Dorst (Surgery subcommittee), 5 top accrual D. Katsaros (Torino), N.S. Reed, (Glasgow, Scotland), Ko van der Velden (Amsterdam), F. Landoni, (Milano), N. Ottevanger Secretary and Chair OVTS (Nijmegen), P. Debruyne (Czak), Emad Shash (Coordinating Research Physician EORTC HQ), Suzy Scholl (TR subcommittee Chair), P. Berns (TR subcommittee co-chair) Corneel Coens (EORTC HQ statistician)